Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02411461
Recruitment Status :
First Posted : April 8, 2015
Results First Posted : June 8, 2018
Last Update Posted : November 13, 2019
Vanderbilt University Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Ashley Shoemaker, Vanderbilt University Medical Center
Pseudohypoparathyroidism type 1a (PHP1a) is a rare disease that causes childhood obesity and learning difficulties. This study will investigate eating behaviors and perform cognitive testing on children with PHP1a. The investigators will compare their results to those of healthy siblings and other obese children.
Pseudohypoparathyroidism type 1a (PHP1a) is a genetic disorder that causes early-onset, syndromic obesity and cognitive impairment. This study aims to evaluate eating behaviors, cognition and executive function in children with PHP1a, compared with healthy siblings and matched obese controls.
Intelligence quotient as measured by Kaufman Brief Intelligence Test, 2nd Edition. This scale yields standard scores where the mean is 100 and one standard deviation is 15. Higher scores indicate better function.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Years to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children with pseudohypoparathyroidism type 1a (PHP1a), their healthy siblings and matched obese controls
Clinical diagnosis of PHP1a, sibling of a patient with PHP1a or matched obese control
Exclusion Criteria (PHP1a):
Treatment with appetite-altering drug or initiation of a new weight loss program in the past 3 months
Type 2 diabetes
Exclusion Criteria (Controls):
Obesity due to a genetic syndrome, growth hormone deficiency, untreated hypothyroidism, Cushing syndrome or exogenous glucocorticoid administration
Weight loss greater than 10% over the previous 6 months